Wellington Management Group LLP Acquires Shares of 59,608 Actinium Pharmaceuticals, Inc. (NYSE:ATNM)

Wellington Management Group LLP bought a new position in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 59,608 shares of the company’s stock, valued at approximately $112,000. Wellington Management Group LLP owned 0.19% of Actinium Pharmaceuticals at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Renaissance Technologies LLC acquired a new stake in Actinium Pharmaceuticals during the 2nd quarter valued at $142,000. Bank of New York Mellon Corp boosted its position in Actinium Pharmaceuticals by 28.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 86,401 shares of the company’s stock valued at $639,000 after buying an additional 19,035 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new stake in shares of Actinium Pharmaceuticals during the second quarter valued at about $92,000. Creative Financial Designs Inc. ADV increased its position in shares of Actinium Pharmaceuticals by 183.0% during the third quarter. Creative Financial Designs Inc. ADV now owns 63,785 shares of the company’s stock worth $120,000 after acquiring an additional 41,250 shares during the last quarter. Finally, Marshall Wace LLP lifted its stake in shares of Actinium Pharmaceuticals by 67.9% in the second quarter. Marshall Wace LLP now owns 256,026 shares of the company’s stock worth $1,895,000 after acquiring an additional 103,557 shares in the last quarter. Institutional investors and hedge funds own 27.50% of the company’s stock.

Actinium Pharmaceuticals Price Performance

Shares of ATNM opened at $1.29 on Friday. The company has a market capitalization of $40.24 million, a PE ratio of -0.93 and a beta of 0.07. The stock’s fifty day moving average price is $1.56. Actinium Pharmaceuticals, Inc. has a 12-month low of $1.10 and a 12-month high of $10.24.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Stephens restated an “overweight” rating and set a $5.00 price objective on shares of Actinium Pharmaceuticals in a research note on Tuesday, November 19th. HC Wainwright reissued a “buy” rating and set a $4.00 price target on shares of Actinium Pharmaceuticals in a research report on Friday, November 15th. Finally, StockNews.com lowered shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, November 11th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $7.40.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).